REG - Thalia Therapeutics - Change of Registered Address
Today 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST0074Ba&default-theme=true
RNS Number : 0074B Thalia Therapeutics PLC 20 April 2026
20 April 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
Change of Registered Address
Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its
proprietary gene delivery system to enable advanced therapies for cancer and
other diseases, announces that it has changed its registered address to 2
Portman Street, London, W1H 6DU with immediate effect.
- Ends -
For more information please contact:
Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer Via Thalia Investor Hub
https://investors.thaliatx.com/link/y5RKGe
(https://investors.thaliatx.com/link/y5RKGe)
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
Guy McDougall
Northstar Communications Limited Tel: +44 (0)20 7183 2463
Investor Relations
Sarah Hollins
About Thalia Therapeutics plc
Thalia Therapeutics plc is a pre-clinical biotech company focused on
developing innovative RNA therapeutics and novel delivery systems to address
high unmet needs in global healthcare.
RNA therapeutics is one of the most rapidly growing therapeutic sectors that
is set to impact the treatment of a wide range of diseases. Thalia
Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics
for cardiovascular and other diseases, as well as developing Nuvec®, its
proprietary gene delivery system, to further differentiate its therapeutic
assets.
Nuvec® addresses multiple challenges associated with RNA therapeutics
manufacturing and delivery, including the ability to deliver multiple RNA
therapies in a single particle, ease of manufacturing, protection of the RNA
payload to enable oral delivery, avoidance of unwanted immune responses, and
excellent stability and storage.
For further information visit www.thaliatx.com (http://www.thaliatx.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END CROKZGMDVNZGVZM
Copyright 2019 Regulatory News Service, all rights reserved